# Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

> **NCT07202598** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (estimated)

## Conditions studied

- Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

## Interventions

- **DRUG:** Emapalumab

## Key facts

- **NCT ID:** NCT07202598
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-12
- **Primary completion:** 2031-03-31
- **Final completion:** 2031-09-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07202598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07202598, "Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07202598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*